Tuesday, February 10, 2015 2:52:21 PM
Don't forget, you have a good chunk of warrants set to expire starting next month and running into next year. Not sure of the exact amount. That should help offset future dilution, if not exercised. And I would think in order to exercise those .77 warrants, the stock would have to be a sufficient amount higher than .77. Or perhaps, the stock trades in a range the warrant holders feel comfortable with. That's a nice cash infusion, which would probably minimize the effect as well.
The important thing to remember. Is the growth exhibited by CYRX, greater than the rate of dilution. I suspect Cryoport will be an 80/90 million share company. When one evaluates all components. The portal, the patents, the partnerships, the quality customer base, tax losses carryforward, and future growth, one can start to place an estimated value on the stock.
At today's market cap, the stock is trading at the present valuation of the technology!
The important thing to remember. Is the growth exhibited by CYRX, greater than the rate of dilution. I suspect Cryoport will be an 80/90 million share company. When one evaluates all components. The portal, the patents, the partnerships, the quality customer base, tax losses carryforward, and future growth, one can start to place an estimated value on the stock.
At today's market cap, the stock is trading at the present valuation of the technology!
Recent CYRX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 06:36:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:30:40 PM
- Cryoport Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/04/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 12:00:17 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/22/2026 08:32:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:31:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/22/2026 08:30:45 PM
- Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026 • PR Newswire (US) • 04/20/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 10:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:01:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:00:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:00:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:01:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:00:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:00:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/12/2026 08:17:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 10:10:46 PM
- Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 03/03/2026 09:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 • PR Newswire (US) • 02/17/2026 01:00:00 PM
- Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series • PR Newswire (US) • 02/11/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/05/2026 09:56:32 PM
